ISSN 1662-4009 (online)

ey0019.7-13 | Basic Science | ESPEYB19

7.13. Multi- and transgenerational outcomes of an exposure to a mixture of endocrine-disrupting chemicals (EDCs) on puberty and maternal behavior in the female rat

D Lopez-Rodriguez , CF Aylwin , V Delli , E Sevrin , M Campanile , M Martin , D Franssen , A Gerard , S Blacher , E Tirelli , A Noel , A Lomniczi , AS Parent

Environ Health Perspect.2021 Aug;129(8):87003. doi: 10.1289/EHP8795. Epub 2021 Aug 12. PMID: 34383603. https://ehp.niehs.nih.gov/doi/10.1289/EHP8795?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmedBrief Summary: Using a rode...

ey0019.12-2 | New data on the epidemiology of T2DM in children | ESPEYB19

12.2. Type 2 diabetes in prepubertal children

MJ Astudillo M, Tosur M, Castillo B, Rafaey A, Siller AF, Nieto J, Sisley S, McKay S, Nella AA, Balasubramanyam A, Bacha F, Redondo

Pediatric diabetes 2021;22(7):946-50. doi: 10.1111/pedi.13254Brief Summary: This retrospective study describes the characteristics of 35 prepubertal children diagnosed with T2DM during 2016–2019 in Houston, Texas. These children had severe obesity, insulin resistance and dyslipidemia.Comment: We were all appalled when the first incidence of T2DM in a 5-year-old girl was...

ey0019.13-10 | Diabetes | ESPEYB19

13.10. Hemoglobin A1c trajectories in the first 18 months after diabetes diagnosis in the SWEET diabetes registry

P Prahalad , A Schwandt , S Besancon , M Mohan , B Obermannova , M Kershaw , R Bonfanti , A Pundziute Lycka , R Hanas , K Casteels , the SWEET Study Group

prahalad@stanford.edu Pediatr Diabetes 2022; 23: 228–236. doi: 10.1111/pedi.13278Brief Summary: Analysis of the multi-national SWEET diabetes registry showed that mean HbA1c in youth is highest at diagnosis and lowest at 4 to 5 months post-diagnosis. The HbA1c trajectory was lower in countries with nationalized health insurance. High gross domestic p...

ey0017.5-5 | Advances in Clinical Practice | ESPEYB17

5.5. Six-year follow-up of a trial of antenatal vitamin D for asthma reduction

AA Litonjua , VJ Carey , N Laranjo , BJ Stubbs , H Mirzakhani , GT O’Connor , M Sandel , A Beigelman , LB Bacharier , RS Zeiger , M Schatz , BW Hollis , ST Weiss

To read the full abstract: N Engl J Med. 2020;382(6):525–533.In brief: High dose vitamin D supplementation of 4400 IU compared with 400 IU during the prenatal period alone to mothers of offspring at risk for asthma did not influence the incidence of asthma and recurrent wheeze in children aged 6-years.Commentary: Vitamin D deficiency has been im...

ey0017.9-1 | Fertility-Related Issues | ESPEYB17

9.1. Anti-Mullerian hormone and Inhibin B after stem cell transplant in childhood: A comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens

A Leiper , M Houwing , EG Davies , K Rao , S Burns , E Morris , J Laven , AL van der Kooi , M van den Heuvel Eibrink , S Nussey

To read the full abstract: Bone Marrow Transplant. 2020 Apr 24. doi: 10.1038/s41409-020-0914-5. Epub ahead of print. a.leiper@nhs.netAnti-Müllerian hormone (AMH), secreted by granulosa cells of growing pre- and early antral ovarian follicles, reflects the reserve of primordial ovarian follicles at any time from birth to menopause. Serum AMH leve...

ey0016.3-13 | Graves’ Disease | ESPEYB16

3.13. Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial

M Cole , AM Hynes , D Howel , L Hall , M Abinun , A Allahabadia , T Barrett , K Boelaert , AJ Drake , P Dimitri , J Kirk , N Zammitt , S Pearce , T Cheetham

To read the full abstract: BMJ Open. 2019;9:e024705.This protocol paper describes an innovative phase II trial to study the effect of a single low dose of adjuvant rituximab (a chimeric anti-B-cell monoclonal antibody targeting the surface molecule CD20) compared to classical carbimazole therapy in adolescents and young adults with Graves’ disease. Carbimazole treatment will be stop...

ey0016.3-16 | New Guidelines | ESPEYB16

3.16. 2018 European Thyroid Association (ETA) Guidelines on the diagnosis and management of central hypothyroidism

L Persani , G Brabant , M Dattani , M Bonomi , U Feldt-Rasmussen , E Fliers , A Gruters , D Maiter , N Schoenmakers , ASP van Trotsenburg

Eur Thyroid J. 2018;7:225-37. doi: 10.1159/000491388. Epub 2018 Jul 19https://www.ncbi.nlm.nih.gov/pubmed/30374425Diagnosis and treatment of central hypothyroidism are much more complex than for primary hypothyroidism. For the first time, guidelines summarize all the available evidence to provide a thorough state of...

ey0016.8-2 | New Mechanisms | ESPEYB16

8.2. Isolation and characterization of adrenocortical progenitors involved in the adaptation to stress

C Steenblock , MF Rubin de Celis , LF Delgadillo Silva , V Pawolski , A Brennand , M Werdermann , I Berger , A Santambrogio , M Peitzsch , CL Andoniadou , AV Schally , SR Bornstein

To read the full abstract: Proc Natl Acad Sci USA. 2018; 115(51): 12997–13002.Humans are constantly challenged by multiple stressors, to which the body’s response and adaptation are essential. The adrenal gland plays a major role in the response to both physiological challenges and stress. Maintenance of the adrenal is partly accomplished by proliferation and differentiat...

ey0016.8-10 | Clinical Trials - New Treatments | ESPEYB16

8.10. Treatment of Primary Aldosteronism with mTORC1 Inhibitors

B Trinh , M Hepprich , MJ Betz , T Burkard , C Cavelti-Weder , E Seelig , F Meienberg , DV Kratschmar , F Beuschlein , M Reincke , A Odermatt , MN Hall , MY Donath , MM Swierczynska

To read the full abstract: J Clin Endocrinol Metab. 2019; pii: jc.2019–00563.Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, affecting ~6% of the adult general hypertensive population. Patients with PA are at increased risk of cerebrovascular and cardiovascular morbidity, renal abnormalities and metabolic syndrome. The activity of mTORC1 ...

ey0016.14-18 | (1) | ESPEYB16

14.18. Darolutamide in nonmetastatic, castration-resistant prostate cancer

K Fizazi , N Shore , TL Tammela , A Ulys , E Vjaters , S Polyakov , M Jievaltas , M Luz , B Alekseev , I Kuss , C Kappeler , A Snapir , T Sarapohja , MR Smith , A Investigators

To read the full abstract: N Engl J Med 2019;380:1235–1246This paper reports a randomized, double-blind, placebo-controlled, phase 3 trial of darolutamide, a novel oral androgen-receptor antagonist, in 1509 men with non-metastatic, castration-resistant prostate cancer. Median metastasis-free survival was significantly longer with darolutamide (40.4 months) than placebo (18.4 ...